Lamotrigine Tablet
Product Images NDC 51672-4252

View Photos of Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 12 technical images submitted to the FDA as part of the official labeling for Lamotrigine (NDC 51672-4252). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Sun Pharmaceutical Industries, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Container Label (100 mg Label)

Container Label (100 mg Label)
Lamotrigine Orally Disintegrating Tablets USP 100 mg packaging label from Sun Pharmaceutical Industries, Inc. The label includes product name, strength (100 mg), dosage form (orally disintegrating tablets), quantity (30 tablets), and storage instructions. It also displays the NDC 51672-4254-6 barcode and caution to verify the product dispensed along with a note to dispense the accompanying Medication Guide to patients.*
FDA Label Image

Container Label (200 mg Label)

Container Label (200 mg Label)
Lamotrigine Orally Disintegrating Tablets USP 200 mg label from Sun Pharmaceutical Industries, Inc. This prescription oral tablet packaging indicates a 30 tablet count. The label includes dosage information, storage instructions, a caution to verify the product, and manufacturer details including Taro Pharmaceutical Industries Ltd. and distributor Sun Pharmaceutical Industries, Inc.*
FDA Label Image

Container Label (25 mg Label)

Container Label (25 mg Label)
Label for Lamotrigine orally disintegrating tablets, USP 25 mg by Sun Pharmaceutical Industries, Inc. The label indicates 30 tablets per package, with caution to verify product dispensed and to provide the medication guide to each patient. It includes storage instructions, usage directions reference, child-resistant package note, and manufacturer and distributor details.*
FDA Label Image

Container Label (50 mg Label)

Container Label (50 mg Label)
Label for Lamotrigine Orally Disintegrating Tablets, USP, 50 mg strength. The label shows it is a prescription drug with 30 tablets per package, labeled by Sun Pharmaceutical Industries, Inc. It includes dosage instructions, storage conditions, caution to verify product dispensed, and manufacturer details from Taro Pharmaceutical Industries Ltd. The label also references a medication guide URL and states the package is child-resistant.*
FDA Label Image

Chemical Structure (Lamotrigine 01)

Chemical Structure (Lamotrigine 01)
Chemical structure of lamotrigine, showing a dichlorophenyl group connected to a triazine ring with amino substituents, corresponding to the active ingredient in LAMOTRIGINE oral tablets by Sun Pharmaceutical Industries, Inc.*
FDA Label Image

Figure 1 (Lamotrigine 02)

Figure 1 (Lamotrigine 02)
A line graph showing failure probability (%) on the y-axis and weeks on the x-axis up to 100 weeks. It compares two groups labeled Placebo and Lamotrigine OD Tablets, with censored data points marked. The graph tracks failure probability over time for these two groups.*
FDA Label Image

Figure 2 (Lamotrigine 03)

Figure 2 (Lamotrigine 03)
A line chart depicting failure probability (%) over time in weeks for Lamotrigine OD Tablets versus Placebo. The chart shows cumulative failure probability with separate curves for Lamotrigine OD Tablets and Placebo, with indication of censored data points.*
FDA Label Image

Pg 1 (Pg 1)

Pg 1 (Pg 1)
Medication guide text panel for Lamotrigine orally disintegrating tablets, USP. It outlines key safety information including serious skin rash risks, other serious reactions, and heart-related warnings. The guide details symptoms that require immediate healthcare provider consultation and advises patients on important precautions when using the medication.*
FDA Label Image

Pg 2 (Pg 2)

Pg 2 (Pg 2)
This image shows a text panel covering safety information about lamotrigine orally disintegrating tablets. It details potential serious side effects including suicidal thoughts or actions, aseptic meningitis symptoms, and advises contacting healthcare providers if symptoms occur. It includes guidance on monitoring for early symptoms and cautions against stopping the medication without medical advice.*
FDA Label Image

Pg 3 (Pg 3)

Pg 3 (Pg 3)
Illustration showing lamotrigine orally disintegrating tablets in four strengths: 25 mg, 50 mg, 100 mg, and 200 mg. Tablets are white to off-white, round, flat-faced with distinct debossed shapes for each strength: 25 mg has plain sides, 50 mg has a "barrel" shape on one side, 100 mg has a "square" shape, and 200 mg has an "octagon" shape on one side. The image aids identification of these tablets to avoid medication errors.*
FDA Label Image

Pg 4 (Pg 4)

Pg 4 (Pg 4)
This text panel provides detailed patient guidance and precautions for lamotrigine orally disintegrating tablets. It includes warnings about allergic reactions, genetic factors, heart and mental health conditions, medication interactions, pregnancy, breastfeeding, dosing instructions, side effects, and safety measures when using lamotrigine tablets. The information emphasizes consulting healthcare providers before starting or changing treatment.*
FDA Label Image

Pg 5 (Pg 5)

Pg 5 (Pg 5)
This text panel provides information on common side effects, storage instructions, safety guidelines, and ingredients for lamotrigine orally disintegrating tablets. It includes warnings against unprescribed use, instructions to keep the medication away from children, and mentions the active ingredient lamotrigine along with inactive ingredients. Distributor and manufacturer details are also present.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.